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The systemic delivery of gene therapeutics by non-viral methods has proven difﬁcult. Transfection
systems that are performing well in vitro have been reported to have disadvantageous properties such
as rapid clearance and short circulation time often resulting in poor transfection efﬁciency when
applied in vivo. Large unilaminary vesicles (LUV) with encapsulated nucleic acids designated stabilized-
plasmid-lipo-particle (SPLP) have showed promising results in terms of systemic stability and
accumulation in tumor tissue due to the enhanced permeability and retention effect (EPR). We have
developed a simple protocol for the research-scale preparation of SPLPs from commercially available
reagents with high amounts of encapsulated plasmid DNA. The SPLPs show properties of promising
accumulation in tumor tissue in comparison to other organs when intravenously injected into
xenograft tumor-bearing nude mice. Although transcriptionally targeted suicide gene therapy was
not achieved, the SPLPs were capable of mediating reporter gene transfection in subcutaneous ﬂank
tumors originating from human small cell lung cancer.
& 2011 Elsevier B.V. All rights reserved.1. Introduction
In the ﬁeld of gene therapy, efﬁcient gene delivery in vivo
based on non-viral methods remains a major challenge, with an
overwhelming variety of polymeric and liposomal compounds
being tested [1]. A major obstacle has been the fact that extremely
efﬁcient methods involving cationic liposomes for gene delivery
to cells in vitro, perform very poorly when tested in animals [2].
Although a regime of transfection-potent lipoplexes has been
established in vitro [3], in vivo applications require different
physical–chemical properties and only limited information about
these have been described.
The development of liposomal carriers with enhanced sys-
temic stability has mainly been advanced by the liposomal
formulation of chemotherapeutics, i.e. doxorubicin into DOXILs
that is FDA-approved for use against several cancers [4]. Here all rights reserved.
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(T. Gjetting).great advantage of therapeutic efﬁciency over the naked drugs
has been accomplished [5]. A great accumulation in disease area,
i.e. tumor tissue due to the so-called enhanced permeability and
retention effect (EPR) is a hallmark of these liposomal formula-
tions [6] where the property of long circulation is accomplished
by a 5–10% PEG polymers screen on the liposomal surface.
Furthermore, efﬁcient encapsulation of plasmid DNA in lipo-
somes can be achieved using an ethanol-mediated condensation
procedure [7,8], and this was established in our laboratory [9].
The technology of stabilized plasmid lipo-particles (SPLPs) has
progressed in recent years [10] and we decided to investigate
these methods for laboratory scale studies of a gene therapy
strategy in mice using conventional lipid reagents, hence we
included a tritium-labeled lipid in the formulation enabling
evaluation of systemic circulation and biodistribution of SPLPs
[11]. A robust laboratory-scale protocol allows for researchers to
perform experiments investigating the biological properties of
SPLPs and the interaction with the biological milieu in order to
characterize the barriers to successful gene delivery.
Aiming at gene therapy of small cell lung carcinoma (SCLC)
[12] we have recently showed high and speciﬁc effect of a suicide
gene therapy system [13]. At the time of diagnosis SCLC often
appears disseminated to various extra-thoracic organs [14], and
therefore a systemic distribution of the therapeutic agent is
T. Gjetting et al. / Results in Pharma Sciences 1 (2011) 49–5650demanded. Hence in the current study we have exploited the
potential of transcriptionally targeted suicide gene therapy using
SPLPs as a delivery vehicle for systemic treatment of a mouse
model of SCLC.2. Materials and methods
2.1. Materials
All chemicals, e.g. synthetic cholesterol were purchased from
Sigma-Aldrich Inc. (Brøndby, Denmark) unless otherwise stated.
DDAB: Dimethyl-dioctadecyl-ammonium bromide, DSPC (1,2-dis-
tearoyl-sn-glycero-3-phosphocholine) and DSPE-PEG2000 (1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(poly-
ethylene glycol)-2000]) were purchased from Avanti Polar Lipids
Inc. (Alabaster, AL, USA) [1,2-3H]-Cholesteryl Hexadecyl Ether
(3H-CHE) was purchased from Perkin Elmer (Skovlunde, Denmark).
High quality plasmids; pCMV-LUC (sequence available upon
request) and pEGFP-N1 (Clontech, Mountain View, CA, USA) pre-
parations were made with the Endo-free Giga kit from Qiagen
GmbH (Hilden, Germany) according to the manufacturer’s instruc-
tions. Glassware used for lipid work was washed and rinsed in mQ
water, baked at 180 1C for 6 h and de-dusted by pressurized air
prior to use. Lipid solutions in chloroform were handled with
gastight glass syringes (Hamilton, VWR, Herlev, Denmark) reserved
for this purpose. Syringes were rinsed with chloroform and 20%
EtOH in water only.
The H1299 and NCI-H69 cell lines (obtained from ATCC, Boras,
Sweden) were cultivated in RPMI medium supplemented with pen-
strep and 10% fetal calf serum (Invitrogen Inc., Taastrup, Denmark).
Six-week old male NMRI mice were from Taconic Europe (Lille
Skensved, Denmark) and housed at Department of Experimental
Medicine, University of Copenhagen. All animal experiments were
performed according to ethical guidelines and under valid license
from the Danish Animal Experimentation Board.
2.2. Methods
2.2.1. Preparation of SPLPs: Cholesterol/DSPC/DDAB/DSPE-PEG2000
liposomes encapsulating plasmid DNA
Chloroform solutions of lipids (10–20 mg/ml) were mixed in a
1275 mm2 glass tube (Thermo Fischer Scientiﬁc, Slangerup,
Denmark) at the following composition (20 mmol total lipid,
mole percent): Cholesterol 55%, DSPC 20%, DDAB 15% and DSPE-
PEG2000 10%. In experiments where a radioactive label was used
3H-CHE (50 mCi, 50 Ci/mmol in toluene) was added. The solvent
was evaporated under vortexing and under a thin nitrogen gas
stream allowing a thin, fairly even lipid ﬁlm to form on approxi-
mately 6 cm of the glass surface. High vacuum was applied
overnight to ensure complete solvent evaporation. A Tris–HCl
buffer (300 ml, 50 mM, pH 7.0) was used to hydrate the lipids and
allow for vesicle formation. The tube was rotated and lipids
allowed to hydrate overnight at room temperature. The next
day the liposome preparation was placed in a metal basket and
sonicated for 2 min using a Bransonic water bath (MT-1510,
42 kHz, 80 W, setting ‘‘sonics’’, Branson Ultrasonics, Danbury,
CT, USA). Plasmid DNA (Endo-free GIGA prep, 200 mg, 5.7 mg/ml
in Tris-buffer) was added to the tube and after collecting the
material at the bottom of the tube by a brief spin exactly one
volume of 80% ethanol in Tris-buffer (50 mM, pH 7.0) was added
dropwise and with mixing during one minute.
The tube was closed and subjected to ﬁve cycles of freeze-
thaw between dry ice/EtOH and 37 1C water bath with 2–3 min in
each step. Liposomes were downsized using 11 passes in a hand-
held, small-scale extruder (Avestin Europe GmbH, Mannheim,Germany) with polycarbonate nucleopore ﬁlters (400 nm, 200 nm
and 100 nm, Whatman, Frisenette, Knebel, Denmark). For each
step a small volume of buffer to wash the extruder ensure a
complete liposome recovery. The entire SPLP volume (typically
1 ml) after the extrusion process was transferred to a dialysis
cassette (PIERCE, Thermo, 10 kDa MWCO) and dialyzed against
0.5 l HEPES buffer (pH 7.4) overnight at room temperature with
one buffer exchange.
MALDI-TOF mass spectrometry analysis of liposome prepara-
tion made at 20 mmol scale conﬁrmed the lipids in the composi-
tion and did not reveal any degradation (data not shown).
2.2.2. Characterization of SPLP
Plasmid encapsulation and ability to migrate in an electrical
ﬁeld was investigated using agarose gel electrophoresis [9,15,16].
Samples of SPLP from different stages of the encapsulation
procedure were loaded on a standard 1% agarose–Tris–Borate–
EDTA gel containing 2 mg/ml ethidium bromide. After completion
the gel was photographed under UV light. Subsequently, the
concentration of plasmid DNA in liposome was determined using
a variation of the PicoGreen assay (Invitrogen) as described by
Jeffs et al. [7]. A typical dose for intravenous injection contained
20 mg DNA and 4 mmol lipid in 200 ml HEPES buffer.
A Zetasizer Nano ZS (Malvern Instruments Inc., Malvern, UK)
was used for characterizing the particle size by dynamic light
scattering. Preparations of liposomes were diluted to approxi-
mately 1 mM total lipid and placed in a clear disposable zeta cell
(Malvern). Size was determined using 4 cycles of 3 min. at
standard settings for vesicles and with ‘‘general purpose’’ para-
meter settings. The quality of size measurements given as the
volume-weighted mean diameter were analyzed by evaluating
polydispersity index (PDI), scattering correlation and cumulants
ﬁt. Subsequently, samples were analyzed for zeta potential of
particles using standard settings with three repeated measure-
ments of 20 zeta runs and assessing the quality of measurements
by evaluation of the phase plot.
2.2.3. Gene expression analysis in vitro
Adherent H1299 were plated the day prior to the experiment
in 6-well plates, 300,000 cells per well. NCI-H69 cells growing in
suspension were single-cell resuspended on the day of the
experiment and counted in a hemocytometer using Trypan Blue
(0.4%) staining to discriminate from dead cells before placing
2106 cells in 6 well plates. Forty microlitres (2–4 mg/0.8 mmol)
of plasmid DNA/liposome preparation was added to cells in full
growth medium and incubated for 2 days at 37 1C before analysis
of reporter activity. Here, cultured cells were washed with
phosphate-buffered saline (PBS) and lysed in 100 ml passive lysis
buffer (Promega Inc., Madison, WI, USA) for 10 min. After cen-
trifugation for 1 min, the supernatant was analyzed for luciferase
activity (20 ml, Luciferase kit, Promega) using a luminometer
(Lumat LB9507, Berthold, Bad Wildbad, Germany) and total
protein concentration (20 ml, 10 times diluted, BCA kit, Pierce/
Thermo, Rockford, IL, USA) using an OpsysMR microplate reader
(Dynex Technologies GmbH, Berlin, Germany). Using a puriﬁed,
recombinant ﬁreﬂy luciferase (Promega) for standardization,
luciferase activity was expressed as picogram luciferase enzyme
per milligram of total protein (pg luc/mg protein).
2.2.4. SCLC tumor model establishment and evaluation of growth
The SCLC xenograft model was established as previously
described [13,17]. Brieﬂy, 5106 NCI-H69 cells per ﬂank were
injected subcutaneously into 6–8-week old male nude NMRI
mice. Tumors from injected mice (termed passage 0) were used
for serial transplantation of mice that entered experimental
Fig. 1. Agarose gel electrophoresis/ethidium bromide staining of SPLP samples
(0.6% of a preparation) in different stages of the preparation. Lane 1: DNA size
marker, lane 2: SPLP before extrusion, ethanol added. Lane 3: SPLP extruded
through 100 nm pore ﬁlters, lane 4: SPLP dialyzed into HEPES buffer, lane 5: SPLP
dialyzed and digested with deoxynucleases to degrade externally bound plasmid
DNA. Free plasmid DNA (migrating as ca. 5 kilobase fragment) and encapsulated
DNA that is retained in the loading well.
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animals (passage 2). Xenograft tumors used in the experiments
were passaged up to 4 times. The tumor growth was monitored
by measuring with a caliper the two perpendicular diameters and
the tumor mass was calculated as previously described [13]. For
suicide gene therapy experiments following intravenous injection
of SPLPs, an intraperitoneal dose of 5-ﬂuoro-cytosine (500 mg/kg)
was given the same and the next day when animals were
euthanized after two days for biodistribution measurements [13].
2.2.5. Pharmacokinetics, luciferase activity and biodistribution
in vivo
Tumor-bearing male NMRI nude mice were injected in the
lateral tail vein with 200 ml SPLP (20 mg DNA and 4 mmol lipid)
prepared as described above. One or two days later animals were
euthanized by cervical dislocation and organ samples (tumor,
heart, lung, liver, kidney, spleen and tail (1 cm upward of injec-
tion site); 20–150 mg) were isolated and snap frozen. Organ
samples were mixed with 1 ml passive lysis buffer (Promega
Inc.) supplemented with Protease Inhibitor Cocktail Set III (Merck
Chemicals, Glostrup, Denmark) ground in a ball mill (Qiagen)
using one steel ball (5 mm) and shaking for 6 min. After centri-
fugation for 10 min at 4 1C the supernatant was isolated and
luciferase activity and protein concentration was measured as
described previously.
Using the lipid marker 3H-CHE [11,18], tritium-labeled DNA/
lipoplexes with varying degree of PEGylation were injected in a
single dose (100 ml) containing approximately 1 mCi tritium label.
In these experiments half of the homogenate (500 ml) was
isolated for scintillation counting before centrifugation. If more
than 90% of the counts were found in the tail sample the injection
was considered as failed and the mouse was excluded from the
experiment. Relative distribution of counts in different samples
was calculated as CPM per g tissue sample. For calculation of the
total radioactivity in each organ, a relative organ weight in tumor-
bearing nude NMRI mice per gram body weight was determined
from ten mice with a standard deviation less than 4%. Using this
tabulation the total organ weights in mice could be estimated in
the experiments. Hence the radioactivity accumulating per gram
organ was expressed relative to the injected dose.
Blood samples (100 ml) were drawn from the eye by periobital
plexus puncture after 15 min, 2 h, 5 h and 24 h and immediately
mixed with 10 ml scintillation liquid (UltimaGold, Perkin Elmer,
Skovlunde, Denmark) and counted in a Beckman LS 6500 liquid
scintillation counter (Beckman Instruments, Fullerton, CA, USA).
After the last blood sampling the animals were euthanized and
organs sampled as described above.
2.2.6. Detection of plasmid in mouse tissue samples
Plasmid and chromosomal DNA in homogenates from 5 to
10 mg tissue were puriﬁed using a Gentra Puregene Blood Kit
(Qiagen) and subjected to PCR analysis with the following condi-
tions: Platinum Taq DNA polymerase (1 unit, Invitrogen), 1PCR
buffer, MgCl2 (1.5 mM), dNTP (0.2 mM each), primers (0.2 mM
each) and puriﬁed DNA from tissue (100 ng). The primers
50-GCTAAGAAGGCTGTTCCCTTCCAC-30 and 50-CTGGGTCATCTTTT-
CACGGTTGG-30 amplify a 266 bp fragment from the b-actin gene
using 35 cycles of 20 s at 94 1C, 20 s at 59 1C and 20 s at 72 1C. The
primers 50-GCAAATGGGCGGTAGGCGTGTA-30and 50-TCAGGGG-
GAGGTGTGGGAGGTT-30 amplify a 966 bp fragment from pEGFP-
N1 plasmid using 25 cycles of 20 s at 94 1C, 20 s at 62 1C and 60 s
at 72 1C. The primers 50-GCCTCATAGAACTGCCTGCGTGAGA-30 and
50-CCGCTTCCCCGACTTCCTTAGAGAG-30 amplify a 351 bp frag-
ment from pCMV-LUC plasmid using 25 cycles of 20 s at 94 1C,
20 s at 57 1C and 20 s at 72 1C. The PCR products were subjectedto agarose gel electrophoresis in the presence of ethidium
bromide and photographed using a GelDoc2000 (BIO-RAD).
2.2.7. Immunohistochemical analysis of tumor samples
Cross-sectioned tumors from euthanized mice were ﬁxed
overnight in freshly prepared pH-neutral formaldehyde (4%)
followed by dehydration in 70% ethanol and embedded in
parafﬁn. Four micrometer sections were prepared in a routine
fashion on plus coated slides. The slides were deparafﬁnized,
hydrated, and stained with H&E or using the Vectastain ABC kit
(Vector Laboratories) according to the manufacturer’s instruc-
tions. Polyclonal rabbit anti-GFP (1:3500, Abcam) antibody was
used to detect EGFP expression. Sections were counterstained
with hematoxylin and mounted for microscope evaluations using
an Olympus BX51 microscope (Olympus, Skovlunde, Denmark).3. Results
3.1. SPLP preparation
Conventional lipids (cholesterol 55%, DSPC 20%, DDAB 15% and
DSPE-PEG2000 10% and 3H-CHE) were used for the preparation of
SPLPs. The procedure was carried out at the 20 mmol total lipid
scale using 200 mg reporter expression plasmid DNA. The plasmid
DNA was prepared in-house using an endo-toxin-free GIGA plas-
mid kit. Almost complete DNA encapsulation was achieved in Tris-
buffer at pH 7.0 by a combination of dropwise addition of ethanol
to a ﬁnal concentration of 40% and ﬁve cycles of freeze-thawing
followed by extensive dialysis against HEPES buffer, pH 7.4 in order
to remove the ethanol. At different stages in the procedure samples
were isolated for agarose gel electrophoretic analysis (Fig. 1) [9] to
estimate encapsulation. The sample in lane 2 constitutes 0.6% of a
preparation after mixing of hydrated lipids and DNA and subse-
quent freeze-thawing. Some plasmid DNA is retained in extrusion
ﬁlters, since the sample in lane 3 (0.6% of a preparation) isolated
after extrusion through 100 nm ﬁlters has a lower staining inten-
sity [19]. This could be due to DNA aggregation or semi-precipita-
tion since several bands of DNA migrating higher in the gel than
5 kb are observed in this lane. After dialysis into HEPES buffer and
removal of the ethanol only a very little amount of externally
bound plasmid is seen migrating as a band of approximately 5 kb
(lane 4). The remaining DNA staining is seen near the loading well
indicative of liposome encapsulated plasmid. In lane 5 the sample
has been digested with a mixture of DNase I and Exonuclease III
[20], hence the free DNA, migrating as a 5 kb-band seen in lane 4 is
lost, and only DNA protected in the liposome is seen near the
loading well of the gel. Using standards of puriﬁed plasmid the
PicoGreen assay was used to determine the DNA concentration in
lane 4 and 5 and was estimated to be 18 mg DNA per 200 ml SPLP
preparation used for one tailvein injection, an overall yield of 45%
plasmid encapsulation. A tritium-labeled tracer lipid was added in
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recovery of lipids in the preparation was almost complete yielding
4 mmol total lipid in 200 ml buffer.
We decided to exploit the use of the SPLPs seen in lane 4 as the
amount of plasmid DNA bound externally and released upon
electrophoresis was very low. The SPLPs used for in vivo studies
were characterized regarding their size and charge using dynamic
light scattering. SPLP sample measurements yielded a narrow size
distribution (1–3 nm) with an average of 144 nm713 nm (stan-
dard error of mean, n¼3), a low polydispersity index (0.170.01)
and a slightly negative zeta potential (6.271.3). These proper-
ties are favorable for long-term circulation in that the size should
be low and not positive as this causes retardation in ﬁrst-pass
organs, whereas the neutral or slightly negative charge allows for
long circulation time in the system [4].
3.2. Gene expression analysis in vitro
The dual properties of nanoparticles to be stably, long-circu-
lating and at the same time yield transfection in target tissue
require exploitation of the transfection properties. Dialyzed SPLPs
containing pCMV-LUC plasmid (0.8 mg) were added in full
growth medium to tissue culture cells either easy to transfect,
adherent lung cancer cells H1299 or hard-to-transfect suspension
small cell lung cancer cells NCI-H69 and the luciferase reporter
activity was analyzed two days later (Fig. 2). Compared to cationic
lipoplex-mediated transfection [21] a moderate activity was
measured in H1299 (1474 pg luc per mg protein) and a low
activity was measured in NCI-H69 cells (0.770.2 pg luc per mg
protein). Since we recently showed that the pharmacokinetics of
cationic lipoplexes were poor for systemic treatment of xenograft
ﬂank tumors [21], we decided to investigate the use of SPLPs in
our xenograft tumor model. Furthermore, NCI-H69 tumor micro-
environment may be very different from growth in suspension in
culture media and this could potentially have a beneﬁcial effect in
relation to transfection from accumulating SPLPs.
3.3. Blood half life
The SPLPs with encapsulated plasmid DNA were tested in vivo
using nude mice carrying xenograft ﬂank tumors originating from
human small cell lung cancer [13]. Animals were carrying 1–2
subcutaneous tumors on the ﬂanks and used for experiments when
tumors had reached 200–800 mm3 in size. A typical preparation ofFig. 2. Reporter gene expression by transfection of NCI-H69 (SCLC) and H1299
(NSCLC) cells in vitro. Luciferase activity in cell lysates was measured two days
after transfection and expressed as picogram luciferase per milligram protein.
Data from at least three independent experiments with different SPLP prepara-
tions were collected and the average and standard error of the mean are given.SPLPs (1 ml) was used for 5 animals; each was injected with one
dose of 200 ml intravenously (18 mg DNA, 4 mM lipids).
In Fig. 3 an experiment where blood was sampled by periobital
puncture (eye vein blood) and analyzed for radioactivity by
scintillation counting at different time points (0.25, 2, 5, 22 and
29 h) after injection. An exponential clearance from the blood was
measured and a log–linear regression analysis yielded a half life
estimate, T(1/2)¼10.870.1 h (average7standard error of the
mean). The half life was determined from pooling three indepen-
dent experiments, including a total of 13 mice and sampling up to
48 h after injection.
3.4. Luciferase reporter gene expression in vivo
After having received a single intravenous injection of SPLP,
mice showed normal behavior and were euthanized after 24 h
and organ samples from tumors, heart, lung, liver, kidney and
spleen were collected. The luciferase activity in protein extracts
was assayed, and expressed as pg luciferase per g total protein
(Fig. 4). Two independent experiments were pooled combining
data from a total of 12 mice carrying 21 tumors in total, since
some mice had only one ﬂank tumor. Assay background was
established previously [21] from control animals and determined
to be 10 pg luc per g protein (indicated with dotted line).
Interestingly, luciferase activity was found almost exclusively in
tumor tissue (52715 pg luc per g protein), only a small activity
above background was found in the lung (19712 pg luc per g
protein), although considerable variation between mice was
observed.
3.5. Biodistribution of radioactive lipid and detection
of plasmid DNA
Having measured the blood half life of tracer lipid we wanted
to measure the biodistribution in various organs and the xeno-
graft ﬂank tumors. After either one or two days the mice were
euthanized and tumors, heart, lung, liver, kidney and spleen
tissues were sampled and homogenates were subjected to scin-
tillation counting (Fig. 5). Data for each time point was combined
from two independent SPLP experiments, where n¼4–7 for each
experiment and time point. The amount of radiolabel measured in
samples was extrapolated to whole organ accumulations and
expressed relative to the input dose given by intravenousFig. 3. Blood availability of tritium-labeled SPLP. Following tailvein injection of
SPLP blood samples were drawn by periobital plexus puncture (eye vein blood)
after 15 min, 2 h, 5 h and 22 and 29 h and the amount of radioactivity was
quantiﬁed by scintillation counting. After log-transformation and normalization a
linear model was applied to each mouse data set (n¼4) estimating the halftime
that correspond to a simple exponential clearance. The half life was determined
from combining three independent experiments (n¼4–5) and the average and
standard error of the mean are given.
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to the amount of tissue analyzed and the biodistribution
was expressed as CPM per gram tissue sample. Interestingly,
already after one day we found 10.071.8% of the injected dose
(average7SEM) in the tumor tissue, whereas only smaller
amounts 1.870.3%, 2.470.4% and 3.770.5% were found in heart,
lung and kidney tissue, respectively. Entrapment by the reticu-
loendothelial system was evident, since almost half (41.979.4%)
of the tracer lipid resided in the spleen, presumably due to uptake
by monocytes and macrophages [4,22] and 16.871.5% was found
in liver, presumably due to uptake by Kuppfer cells. After two
days, although the measured radioactivity was lower, a high
relative accumulation in tumor tissue (4.270.9%) persisted andFig. 4. Luciferase reporter gene expression in vivo. 24 h after receiving a single
intravenous injection with 200 ml SPLP, mice were euthanized and organ samples
collected and the luciferase activity in protein extracts was assayed, here
expressed as pg luciferase per g total protein. Two independent experiments
were pooled combining data from a total of 12 mice carrying 21 tumors in total,
since some mice had only one ﬂank tumor. Assay background was at 10 pg luc/g
protein (indicated with dotted line). Only tumor and lung tissues showed mean
activities above background, however, with high variation. Error bars indicated the
standard error of mean.
Fig. 5. Biodistribution of radioactive tracer lipid. The distribution in tumor, heart, lung
after 24 h (top panel) and 48 h (lower panel). The relative distribution of tritium counts
independent experiments (n¼4–7) were pooled and averaged and error bars indicatea shift from spleen (11.070.8) towards liver (12.373.3) and
kidney (3.471.0) was observed, while the amount in heart and
lung remained much lower. When considering the distribution of
radioactivity in the measured samples only, around 20% of the
radiolabel found in the samples was present in the tumor tissue
(Fig. 5, right part).
In order to conﬁrm that plasmid DNA was distributed simi-
larly, DNA was extracted from tissue samples and subjected to
semi-quantitative PCR analysis. Fig. 6 shows the result from
analyzing two representative mice injected with SPLPs containing
either pEGFP-N1 (A) or pCMV-LUC (B) plasmid. Upper panels
show that plasmid is detectable in all tissue samples and that the
amount of PCR product is in good alignment with the distribution
of radioactive lipid in the different organs as shown in Fig. 5.
Lower panels show control ampliﬁcation of a chromosomal DNA
fragment from beta-Actin.
3.6. Immunohistochemical staining against EGFP reporter
in tumor tissue
We examined the reporter gene expression in xenograft
tumors of mice by immunohistochemical staining. One day after
intravenous injection of SPLPs containing pEGFP-N1, mice were
euthanized and tumor tissue analyzed. Fig. 7 shows tumor
sections stained with an antibody recognizing EGFP, hence no
signal is observed in the left panel (A), where the mouse did not
receive a liposome dose. A strong signal in discrete cells is
observed in the right panel (C), where the mouse received an
intratumoral injection of recombinant adenovirus expressing
EGFP [13]. However as shown in the middle panel (B) very low
to undetectable levels of EGFP were observed in tumors from
mice injected with SPLPs containing the pEGFP-N1 plasmid.
3.7. Tumor growth in response to treatment with suicide
gene therapy
We found that the blood circulation time and biodistribution was
independent of the cargo plasmid used and hence we performed an, liver, kidney and spleen total organs was calculated relative to the injected dose
per minutes per gram tissue sample is shown to the right. For each time point two
standard error of the mean.
Fig. 6. Detection of plasmid DNA in tissue samples. Tumor and mouse organ homogenates originating from 5 to 10 mg tissue were subjected to DNA puriﬁcation and the
resulting mix of chromosomal and plasmid DNA was subjected to semi-quantitative PCR analysis. A primer pair amplifying the b-actin gene was used as control (lower
panels). Representable samples from a mouse injected with (A) pEGFP-N1 encapsulated liposome was analyzed with EGFP speciﬁc primers and (B) pCMV-LUC
encapsulated liposome was analyzed with LUC speciﬁc primers (top panels). Agarose gel lanes were loaded with 1: jX174 HaeIII-digested DNA, 2–8: PCR template was
DNA from left-ﬂank tumor, right-ﬂank tumor, heart, lung, liver, kidney and spleen, respectively, 9: blank control without DNA, 10: puriﬁed plasmid.
Fig. 7. Immunohistochemical analysis of EGFP expression in xenograft tumors treated with SPLP encapsulated with pEGFP-N1 plasmid, two days after intravenous
injection. Tumor tissue sections were stained with anti-EGFP antibody (brown color) and counterstained with hematoxylin and eosin, Left panel (a) is from an untreated
tumor, middle panel (b) is from a tumor where the mouse received intravenous SPLP injection and in the right panel (c) the tumor was directly injected with a recombinant
virus expressing EGFP. The scale bar indicates 100 mm.
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recently reported to be useful for SCLC [13]. The SPLPs containing
pINSM1-SCD-FLAG, a plasmid expressing a FLAG-tagged variant of
‘‘super cytosine deaminase’’ from a SCLC-speciﬁc INSM1 promoter,
was intravenously injected and followed by an intraperitoneal
injection of the non-toxic prodrug 5-ﬂuoro-cytosine. Only in cells
expressing the delivered plasmid this compound is converted to the
toxic 5-ﬂuoro-uracil. Using caliper-measurements, we monitored
the tumor growth in mice that received the prodrug and compared
to mice that did not (Fig. 8); however, we did not observe a
difference in growth between the two groups after two days. Using
immunohistochemical staining we analyzed tumor tissue sections
from injected animals for FLAG-tag positive cells [13] indicating
expression of suicide gene and applied a TUNEL assay to visualize
cell death. We were unable to detect the expression of suicide gene
product presumably due to limited transgene expression in accor-
dance with luciferase experiments. No signiﬁcant increase in the
fairly high apoptotic index in the tumor tissue could be observed as
a result of 5-ﬂuoro-cytosine treatment (data not shown). Hence we
noted that the effect of transgene expression was diminishable,
although the accumulation of SPLPs in tumor tissue remained high.Fig. 8. Tumor growth after intravenous administration of SPLPs containing SCLC-
target suicide gene therapy. Top panel (A) shows indexed tumor growth with and
without 5-FC administration and lower panel (B) shows initial tumor volume.
Diamonds represent 5-FC-treated tumors (n¼7, 4 animals) and squares represent
non-5-FC-treated tumors (n¼15, 9 animals).4. Discussion
4.1. Stabilized plasmid lipo-particles
The importance of nanoparticle properties that on one hand
ensure systemic stability by having a PEG layer on the surface and
on the other hand are able to transfect cells with great efﬁciency
once the nanoparticle has arrived at its target site has been
discussed in many papers (e.g. Hatakeyama et al. [23]. One of the
T. Gjetting et al. / Results in Pharma Sciences 1 (2011) 49–56 55most promising strategies involve stabilized plasmid lipo-particles
[10] using custom-designed lipid components including PEGylated
[24] and cationic lipids [25]. Here we tested a formulation of
similar properties from commercially available lipids to assess
nanoparticle properties, systemic stability, transfection efﬁciency
and usefulness in a suicide gene therapy application.
We have previously described the efﬁcient encapsulation of
plasmid DNA into PEGylated immuno-liposomes with 70% of the
plasmid being encapsulated in the interior [9] and while using similar
procedures we obtained SPLPs in approximately 150 nm in size.
In addition to PicoGreen assay, agarose gel electrophoresis
provide a method for evaluating the encapsulation and externally
bound plasmid DNA [9,15,16], and hence we found that plasmid
DNA was effectively encapsulated and protected from nucleases
(Fig. 1) and could be applied to cells and animals without further
puriﬁcation.
A nuclease digestion and subsequent puriﬁcation by size-exclu-
sion chromatography did not change the size of the particles, but
merely caused an unfavorable dilution of the SPLPs. Furthermore,
we measured unchanged luciferase activity in vitro when analyzing
nuclease-treated SPLPs; however, concerns of systemic immune
responses to nucleic acids [26,27] or C-p-G [28] in vivo persist and
could favor additional steps of SPLP puriﬁcation [9,20].
4.2. Transgene expression
When we analyzed the luciferase activities of SPLPs with
encapsulated luciferase reporter plasmid we found considerable
activities in human non-small cell lung cancer H1299 cells. In
small cell lung cancer NCI-H69 cells the luciferase activity was
much lower (Fig. 2). Presumably, this difference reﬂects growth
properties and internalization capabilities of the two cell lines
and has been found with a number of different lipid-based
transfection reagents [13,21] (unpublished data). Nevertheless
xenograft tumors derived from NCI-H69 cells growing on the
ﬂank of nude mice could be transfected with our SPLPs by
intravenous delivery, as we measured a moderate reporter activ-
ity (Fig. 4) comparable to the results of others [10]. This ﬁnding
could relate to the fact that tumor cells that are actively dividing
have fewer intracellular barriers to successful SPLP-mediated
transfection than other diffentiated tissues analyzed.
Furthermore, in lung tissue we measured luciferase activity
above background level, although only a low amount of SPLP
resided in the lung (2–3%, Fig. 5). It could be speculated that a
population of cells in lung capillaries is relatively easy transfected
by lipo-particles and theoretically examination by in situ immu-
nohistochemical methods would elucidate this phenomenon.
Additionally, a careful in situ analysis of transgene expression
may shed light on the location of cells within the tumor that are
successfully transfected by this route of delivery [4] and degree of
extravasation from tumor vasculature as it has been reported in
case of DOXILs [29,30].
However, when attempting to detect EGFP by immunohisto-
chemical staining after intravenous injection of SPLPs with
encapsulated pEGFP-N1 plasmid, we only found very weak or
non-detectable expression in tumor (Fig. 7) and lung tissue
sections (data not shown), hence it is suggested that protein
levels are too low for positive immuno-detection.
4.3. Systemic stability and biodistribution
It has been established that inclusion of a PEG-modiﬁed lipid
in the formulation facilitates long systemic circulation time and
may circumvent immunostimulation and rapid clearing from the
system [31], although recently concerns have been raised regard-
ing immune responses [26]. Prolonged circulation time ofliposomes leads to accumulation at the site of disease, the so-
called enhanced permeability and retention (EPR) effect, presum-
ably due to leaky endothelial lining in the blood vessels and
impaired lymphatic drainage [6]. For a strategy involving gene
therapy against a disseminated cancer EPR ameliorates the
transfection perspective profoundly; not all cells in the body need
to be transfected, hence a targeted gene medicine can be greatly
assisted by ensuring that the circulation time is long enough for
the accumulation in cancer tissue to occur. In the SPLP formula-
tion we included 10% DSPE-mPEG2000, which is the PEG–lipid in
the DOXILs formulation that ensures a very long circulation half
life of 16–30 h in mice [4,32,33].
The SPLPs were prepared with a non-degradable, non-metaboliz-
able radioactive lipid label in the formulation enabling the easy
evaluation of biodistribution by scintillation counting of samples
upon injection of the SPLPs into mice [18]. Hence by blood sampling
in the time after SPLP injection we measured a blood half life of
more than 10 h allowing sufﬁcient time for the EPR effect to work
[34]. Previous work has shown that blood plasma half life of 6–7 h is
sufﬁcient for tumor accumulation of the particles [10,11]. Biodis-
tribution of radioactively labeled SPLPs was calculated in two
different ways. Firstly, the distribution was calculated considering
the total weights of the analyzed organs relative to the injected dose,
and a clearing from the system was found over two days with
increasing accumulation in liver and kidney, while a relatively large
dose was retained in tumor. Secondly, the radiolabel distribution in
the isolated tissue samples was calculated, and here around 20% of
the radioactive lipid resided in tumor tissue one and two days after
intravenous administration. Predominantly the remaining radiolabel
appeared to have been taken up by the reticuloendothelial system,
macrophages and monocytes in the spleen and Kuppfer cells in the
liver [22] and importantly no accumulation in ﬁrst-pass organs was
observed [21].
In addition to tracking the radioactive lipid label we also
performed a PCR analysis of tissue samples in order to verify that
the gene cargo of liposomes was present in the different organs.
Indeed we found that both luciferase and EGFP expression plas-
mids were detected in a semi-quantitative assay in good alignment
with the distribution of the radioactive lipid label (Fig. 6).
4.4. Suicide gene therapy
In our strategy to develop a suicide gene therapy for small cell
lung cancer the most promising system to date is the yeast
cytosine deaminase (YCD) gene fused with the uracil phosphor-
ibosyl transferase (YUPRT) gene driven from the human INSM1
promoter in combination with administration of 5-ﬂuoro-cytosine
(5-FC) prodrug [13]. When we tailvein-injected tumor-bearing
nude mice with suicide gene encapsulating SPLPs and adminis-
tered prodrug intraperitoneally in two preliminary experiments,
we could neither observe a signiﬁcant reduction in tumor size by
caliper measurements (Fig. 8) nor an increase in dead tumor cells
measured by TUNEL-positive cells in ﬁxed tissue sections. A high
apoptotic index of the cancer cells within the tumor could be
masking a subtle effect of the suicide gene therapy treatment
([13], data not shown). Previous trials with this suicide gene
system utilizing intratumoral delivery showed a prompt response
in tumor growth already after one or two days [13], hence these
results are in alignment with the low efﬁciency of transgene
expression as described above using luciferase and EGFP reporters.
Even so, the system constitutes an attractive delivery vehicle
that enables tumor targeting after systemic administration without
causing adverse retention in non-target organs allowing evaluation
of cancer gene therapy strategies within the appropriate tissue of a
xenograft tumor model. Obviously the transfection efﬁciency in
target tissue requires augmentation of the present results with
T. Gjetting et al. / Results in Pharma Sciences 1 (2011) 49–5656commercially available lipids and optimization of lipids formulated
into SPLPs is ongoing [25,35]. Furthermore we are aiming to
incorporate lipids responsive to local tumor environment, e.g.
using pH-sensitive, detachable PEG-moieties [36] or other enzyme
activities found in tumor environment [37] and hereby arriving at a
transfection efﬁciency that is useful in a therapeutic setting.5. Conclusion
A protocol is described for the preparation of SPLPs with
encapsulated plasmid DNA for treatment of SCLC using a tran-
scriptionally targeted suicide gene therapy approach. The system
was tested for systemic delivery to xenograft tumors in nude mice
and showed attractive properties of circulation and tumor accu-
mulation, however without causing effective transfection. The
methods will be useful for investigators, who wish to extend
in vitro studies of controlled release of nucleic acid cargo from
SPLPs into cancer cells to xenograft model tumors in vivo for
example by incorporating bioresponsive components that change
the properties of SPLPs due to local enzymatic activities or pH.Acknowledgment
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